Prognoses of patients with melanoma who continue/discontinue anti-programmed death-1 therapy after achieving a complete response in a real-world setting: a multicentre retrospective study

Kato, Junji; Namikawa, Kenjiro; Uehara, Jiro; Nomura, Mamoru; Nakamura, Yasuhiro; Uhara, Hisashi; Uchi, Hiroshi; Yoshikawa, Shusuke; Kiniwa, Yukiko; Nakamura, Yoshiyuki; Miyagawa, Takuya; Matsushita, Satoru; Takenouchi, Tatsuya; Hatta, Naohito; Ohno, Fumitaka; Maeda, Taku; Fukushima, Satoshi; Yamazaki, Naoya

doi:10.1111/bjd.21276

Cited by 1 publication

(4 citation statements)

References 9 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…In contrast, several retrospective studies on melanoma have reported clinical outcomes after early discontinuation of ICI therapy. [66][67][68] In a real-world analysis of 185 patients with advanced melanoma who discontinued anti-PD-1 treatment in the absence of disease progression or treatment-limiting toxicity, 145 (78%) patients remained free from disease progression. Relapse after treatment discontinuation was infrequent in patients who achieved a CR and were treated for more than 6 months.…”

Section: Immune Checkpoint Inhibitorsmentioning

confidence: 99%

“…Importantly, this study included 12 patients with the acral subtype and 22 with the mucosal subtype, therefore, a sustained clinical benefit may occur regardless of the melanoma subtype. 68 Currently, there are several ongoing clinical trials to determine the optimal duration of ICI treatment for advanced melanoma (Table 2). The STOP-GAP trial in Canada is a randomized phase III trial comparing intermittent anti-PD-1 therapy with standard continuous anti-PD-1 therapy for up to 2 years.…”

Section: Immune Checkpoint Inhibitorsmentioning

confidence: 99%

“…However, the primary endpoint of the CheckMate 153 trial was safety, and efficacy was an exploratory endpoint. In contrast, several retrospective studies on melanoma have reported clinical outcomes after early discontinuation of ICI therapy 66–68 . In a real‐world analysis of 185 patients with advanced melanoma who discontinued anti‐PD‐1 treatment in the absence of disease progression or treatment‐limiting toxicity, 145 (78%) patients remained free from disease progression.…”

Section: Optimal Duration Of Systemic Therapymentioning

confidence: 99%

“…Similarly, a multicenter, retrospective study in Japan with 57 patients who achieved a CR to anti‐PD‐1 monotherapy showed similar PFS after CR between the continuation group ( n = 21) and the discontinuation after >6 months of therapy group ( n = 25); however, poor PFS was observed in the discontinuation after ≤6 months of therapy group ( n = 11). Importantly, this study included 12 patients with the acral subtype and 22 with the mucosal subtype, therefore, a sustained clinical benefit may occur regardless of the melanoma subtype 68 …”

Section: Optimal Duration Of Systemic Therapymentioning

confidence: 99%

See 3 more Smart Citations

Long‐term survival with systemic therapy in the last decade: Can melanoma be cured?

Namikawa,

Nakano,

Ogata

et al. 2024

The Journal of Dermatology

Self Cite

View full text Add to dashboard Cite

Immune checkpoint inhibitors have been shown to prolong survival of patients with several types of cancer, and the finding was first established in melanoma. Previously, systemic therapy for advanced melanoma aimed only at tumor control and palliation of symptoms. However, in recent years, some patients who received systemic therapy have achieved a complete response and survived without continuous treatment for more than several years. This review discusses the long‐term survival rates achieved with currently used systemic therapies and their future perspectives. Long‐term survival is currently most likely to be achieved with the use of the standard‐dose combination of nivolumab plus ipilimumab, however, this regimen is associated with a high frequency of serious or persistent immune‐related adverse events. Several new anti‐PD‐1‐based combination therapies with a better risk–benefit balance are currently under development. Although the acral and mucosal subtypes tend to be less responsive to immune checkpoint inhibitors, anti‐PD‐1‐based combination therapy should continue to be investigated for these subtypes owing to its potential for better long‐term survival. With the development of efficacious immunotherapy and targeted therapy, it is important to determine the optimal duration of systemic therapy to avoid unnecessary health and financial burdens as well as to improve efforts to support long‐term cancer survivors. As the goal of systemic therapy shifts from tumor control to long‐term survival, in future clinical trials, long‐term clinical outcomes should be evaluated to assess the benefits of novel agents.

show abstract

Section: Immune Checkpoint Inhibitorsmentioning

confidence: 99%

Section: Immune Checkpoint Inhibitorsmentioning

confidence: 99%

Section: Optimal Duration Of Systemic Therapymentioning

confidence: 99%

Section: Optimal Duration Of Systemic Therapymentioning

confidence: 99%

See 2 more Smart Citations